377 related articles for article (PubMed ID: 21327753)
1. Trends in chronologic age and infant respiratory syncytial virus hospitalization: an 8-year cohort study.
Fryzek JP; Martone WJ; Groothuis JR
Adv Ther; 2011 Mar; 28(3):195-201. PubMed ID: 21327753
[TBL] [Abstract][Full Text] [Related]
2. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006.
Stockman LJ; Curns AT; Anderson LJ; Fischer-Langley G
Pediatr Infect Dis J; 2012 Jan; 31(1):5-9. PubMed ID: 21817948
[TBL] [Abstract][Full Text] [Related]
3. Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season.
Singleton RJ; Bruden D; Bulkow LR; Varney G; Butler JC
Pediatr Infect Dis J; 2006 Dec; 25(12):1116-22. PubMed ID: 17133156
[TBL] [Abstract][Full Text] [Related]
4. Correlation between respiratory syncytial virus (RSV) test data and hospitalization of children for RSV lower respiratory tract illness in Florida.
Light M; Bauman J; Mavunda K; Malinoski F; Eggleston M
Pediatr Infect Dis J; 2008 Jun; 27(6):512-8. PubMed ID: 18449062
[TBL] [Abstract][Full Text] [Related]
5. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
[TBL] [Abstract][Full Text] [Related]
6. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants.
Singleton R; Dooley L; Bruden D; Raelson S; Butler JC
Pediatr Infect Dis J; 2003 Jun; 22(6):540-5. PubMed ID: 12799511
[TBL] [Abstract][Full Text] [Related]
7. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries.
Simoes EA; Carbonell-Estrany X
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S13-8; discussion S18-20. PubMed ID: 12671448
[TBL] [Abstract][Full Text] [Related]
8. Impact of respiratory syncytial virus infection as a cause of lower respiratory tract infection in children younger than 3 years of age in Japan.
Kaneko M; Watanabe J; Kuwahara M; Ueno E; Hida M; Kinoshita A; Sone T
J Infect; 2002 May; 44(4):240-3. PubMed ID: 12099731
[TBL] [Abstract][Full Text] [Related]
9. Severe bronchiolitis and respiratory syncytial virus among young children in Hawaii.
Yorita KL; Holman RC; Steiner CA; Effler PV; Miyamura J; Forbes S; Anderson LJ; Balaraman V
Pediatr Infect Dis J; 2007 Dec; 26(12):1081-8. PubMed ID: 18043442
[TBL] [Abstract][Full Text] [Related]
10. Respiratory syncytial virus season and hospitalizations in the Alaskan Yukon-Kuskokwim Delta.
Singleton RJ; Bruden D; Bulkow LR
Pediatr Infect Dis J; 2007 Nov; 26(11 Suppl):S46-50. PubMed ID: 18090200
[TBL] [Abstract][Full Text] [Related]
11. Recurrent wheezing after respiratory syncytial virus or non-respiratory syncytial virus bronchiolitis in infancy: a 3-year follow-up.
Valkonen H; Waris M; Ruohola A; Ruuskanen O; Heikkinen T
Allergy; 2009 Sep; 64(9):1359-65. PubMed ID: 19416146
[TBL] [Abstract][Full Text] [Related]
12. Respiratory syncytial virus risk factors in late preterm infants.
Lanari M; Silvestri M; Rossi GA
J Matern Fetal Neonatal Med; 2009; 22 Suppl 3():102-7. PubMed ID: 19925369
[TBL] [Abstract][Full Text] [Related]
13. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
14. Total healthcare costs in the US for preterm infants with respiratory syncytial virus lower respiratory infection in the first year of life requiring medical attention.
Stewart DL; Romero JR; Buysman EK; Fernandes AW; Mahadevia PJ
Curr Med Res Opin; 2009 Nov; 25(11):2795-804. PubMed ID: 19788406
[TBL] [Abstract][Full Text] [Related]
15. The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States.
Kong AM; Krilov LR; Fergie J; Goldstein M; Diakun D; Wade SW; Pavilack M; McLaurin KK
Am J Perinatol; 2018 Jan; 35(2):192-200. PubMed ID: 28881376
[TBL] [Abstract][Full Text] [Related]
16. Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?
Bjornson C; Chan P; Li A; Paes B; Lanctôt KL; Mitchell I
Eur J Clin Microbiol Infect Dis; 2018 Jun; 37(6):1113-1118. PubMed ID: 29557081
[TBL] [Abstract][Full Text] [Related]
17. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
[TBL] [Abstract][Full Text] [Related]
18. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002.
Henckel E; Luthander J; Berggren E; Kapadia H; Naver L; Norman M; Bennet R; Eriksson M
Pediatr Infect Dis J; 2004 Jan; 23(1):27-31. PubMed ID: 14743042
[TBL] [Abstract][Full Text] [Related]
19. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.
Lacaze-Masmonteil T; Rozé JC; Fauroux B;
Pediatr Pulmonol; 2002 Sep; 34(3):181-8. PubMed ID: 12203846
[TBL] [Abstract][Full Text] [Related]
20. Hospitalization for respiratory syncytial virus illness in Down syndrome following prophylaxis with palivizumab.
Paes B; Mitchell I; Yi H; Li A; Lanctôt KL;
Pediatr Infect Dis J; 2014 Feb; 33(2):e29-33. PubMed ID: 23989104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
